Inquiry Basket
CAS No.: 141304-51-0
Cat No.: BADC-00593
4.5 
Apaziquone is an indolequinone bioreductive prodrug and analog of mitomycin C with potential antineoplastic and radiosensitization activities. Apaziquone is converted to active metabolites in hypoxic cells by intracellular reductases, which are present in greater amounts in hypoxic tumor cells. The active metabolites alkylate DNA, resulting in apoptotic cell death.
Structure of 141304-51-0
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
| NCT Number | Condition Or Disease | Phase | Start Date | Sponsor | Status |
|---|---|---|---|---|---|
| NCT01469221 | Bladder Cancer | Phase 3 | 2017-12-15 | Spectrum Pharmaceuticals, Inc | Terminated (Business reason) |
| NCT00141531 | Bladder Neoplasms | Phase 2 | 2012-06-14 | Spectrum Pharmaceuticals, Inc | Completed |
| NCT00461591 | Bladder Cancer | Phase 3 | 2021-03-30 | Spectrum Pharmaceuticals, Inc | Completed |
| NCT02563561 | Bladder Cancer | Phase 3 | 2021-10-27 | Spectrum Pharmaceuticals, Inc | Terminated |
| NCT03224182 | Bladder Cancer | Phase 3 | 2021-09-28 | Spectrum Pharmaceuticals, Inc | Terminated (Suspended development) |
Apaziquone
Required fields are marked with *
Apaziquone
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
